During the last session, Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s traded shares were 0.42 million, with the beta value of the company hitting 1.43. At the end of the trading day, the stock’s price was $5.37, reflecting an intraday gain of 0.94% or $0.05. The 52-week high for the ALDX share is $6.55, that puts it down -21.97 from that peak though still a striking 73.56% gain since the share price plummeted to a 52-week low of $1.42. The company’s market capitalization is $319.09M, and the average intraday trading volume over the past 10 days was 0.47 million shares, and the average trade volume was 516.56K shares over the past three months.
Aldeyra Therapeutics Inc (ALDX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ALDX has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.25.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aldeyra Therapeutics Inc (NASDAQ:ALDX) trade information
Aldeyra Therapeutics Inc (ALDX) registered a 0.94% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.94% in intraday trading to $5.37, hitting a weekly high. The stock’s 5-day price performance is 0.56%, and it has moved by -13.25% in 30 days. Based on these gigs, the overall price performance for the year is -2.89%. The short interest in Aldeyra Therapeutics Inc (NASDAQ:ALDX) is 3.0 million shares and it means that shorts have 5.57 day(s) to cover.
The consensus price target of analysts on Wall Street is $11, which implies an increase of 51.18% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $12 respectively. As a result, ALDX is trading at a discount of -123.46% off the target high and -86.22% off the low.
Aldeyra Therapeutics Inc (ALDX) estimates and forecasts
Statistics show that Aldeyra Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Aldeyra Therapeutics Inc (ALDX) shares have gone up 26.35% during the last six months, with a year-to-date growth rate more than the industry average at 20.31% against 19.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -78.60% this quarter and then jump 125.00% in the quarter after that.
Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 28.43M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.70%. While earnings are projected to return 19.81% in 2024.
ALDX Dividends
Aldeyra Therapeutics Inc is due to release its next quarterly earnings on 2024-Nov-01. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders
Aldeyra Therapeutics Inc insiders own 2.45% of total outstanding shares while institutional holders control 60.42%, with the float percentage being 61.94%. PERCEPTIVE ADVISORS LLC is the largest shareholder of the company, while 143.0 institutions own stock in it. As of 2024-06-30, the company held over 9.28 million shares (or 15.6121% of all shares), a total value of $30.7 million in shares.
The next largest institutional holding, with 5.48 million shares, is of KNOLL CAPITAL MANAGEMENT, LLC’s that is approximately 9.2158% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $18.12 million.
